Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Sep;23(3):358-365.
doi: 10.1111/vco.13060. Epub 2025 Apr 22.

Vinorelbine as a Rescue Treatment for Canine Histiocytic Sarcoma: A Multicentre Retrospective Study of 18 Dogs

Nina Vigevani  1 , Carmit Chalfon  2 , Alexandra Guillén  3 , Laura Marconato  4 , Isabel Amores-Fuster  1 , Jean-Benoit Tanis  1   5 , Riccardo Finotello  1
Affiliations
Multicenter Study

Vinorelbine as a Rescue Treatment for Canine Histiocytic Sarcoma: A Multicentre Retrospective Study of 18 Dogs

Nina Vigevani et al. Vet Comp Oncol. 2025 Sep.

Abstract

Histiocytic sarcoma (HS) is a highly metastatic cancer, and while response to several chemotherapy agents has been studied, the outcome remains poor. Vinorelbine (VNB) has been considered a possible treatment option, but data are limited. The aim of this study was to assess the efficacy and toxicity of VNB in canine HS. Medical records of dogs with HS, treated with VNB as first-line or rescue treatment, were reviewed. Overall response rate (ORR), progression-free survival (PFS), overall survival post-VNB (post.VNB.OST) and adverse events were evaluated. Associations between outcome measures and signalment, disease extent/location, diagnostic modality and response to previous chemotherapies were analysed. Eighteen dogs were included: 12 disseminated and six localised HS. VNB was a rescue treatment in all dogs. ORR was 38.9% [two complete responses (CR), five partial responses (PR)] including two dogs showing delayed best responses. Median PFS and post-VNB-OST for all dogs were 49 (95% CI: 33-166) and 75.5 days (95% CI: 55-174), respectively. Responders showed significantly longer median PFS (120 days) compared to non-responders (41 days). None of the other factors analysed were associated with ORR, PFS and post-VNB-OST, including pulmonary location. Neutropenia and gastrointestinal toxicity were common; however, the majority were low-grade with no hospitalisation required. Vinorelbine can be an effective and safe treatment for canine HS; disease location alone may not be a key predictive factor for VNB response and outcome. Further prospective studies on larger cohorts are required to confirm these findings.

Keywords: cancer; canine; histiocytic sarcoma; vinorelbine.

PubMed Disclaimer

References

    1. P. F. Moore , “Histiocytic Diseases,” Veterinary Clinics of North America. Small Animal Practice 53, no. 1 (2023): 121–140.
    1. K. M. Boerkamp , F. G. van Steenbeek , L. C. Penning , et al., “The Two Main Forms of Histiocytic Sarcoma in the Predisposed Flatcoated Retriever Dog Display Variation in Gene Expression,” PLoS One 9, no. 6 (2014): e98258.
    1. S. A. Erich , F. Constantino‐Casas , J. M. Dobson , and E. Teske , “Morphological Distinction of Histiocytic Sarcoma From Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers,” In Vivo 32, no. 1 (2018): 7–17.
    1. J. Fidel , I. Schiller , B. Hauser , et al., “Histiocytic Sarcomas in Flat‐Coated Retrievers: A Summary of 37 Cases (November 1998–March 2005),” Veterinary and Comparative Oncology 4, no. 2 (2006): 63–74.
    1. Y. Kagawa , Y. Nakano , T. Kobayashi , K. Asano , and S. Takagi , “Localized Pulmonary Histiocytic Sarcomas in Pembroke Welsh Corgi,” Journal of Veterinary Medical Science 77, no. 12 (2015): 1659–1661.

Publication types

Substances

LinkOut - more resources